Pentarin Collaborations

Tarveda’s Pentarin™ platform enables the creation of proprietary, miniature drug conjugates that are applicable to a wide range of targets. Tarveda is developing a proprietary pipeline of novel miniature drug conjugates, based on targeting ligands, unique optimized linker approaches and a range of effective payloads.

Tarveda has an exclusive license agreement with Madrigal Pharmaceuticals for Madrigal’s HSP90 drug conjugate platform. This worldwide agreement provides for the discovery, development and commercialization by Tarveda of products based on Madrigal’s HSP90 drug conjugate platform including the lead clinical candidate, PEN-866.  Tarveda is applying its Pentarin technologies to enhance and further advance this HSP90 platform.

HSP90 activation is common in many tumor types with the opportunity to accumulate HSP90 drug conjugates comprising proprietary potent payloads to develop multiple unique product candidates. The payloads can include cytotxic compounds and enzyme inhibitors to specific therapeutic targets, such as protein kinases. In each conjugate the linker chemistry is optimized for sustained release of the fully active therapeutic payload at concentrations to drive efficacy in the tumor.

Our Pentarin platform can be applied to strategic collaborations in a range of ways:

  • Strategic partners can participate in the development of proprietary Pentarins that are in Tarveda’s development pipeline;
  • Strategic partners collaborate on the development of new miniaturized drug conjugates;
  • Tarveda’s Pentarin platform is positioned to develop miniaturized drug conjugate that incorporate a partner’s proprietary payloads and/or targeting ligands.

To inquire about Pentarin collaborations, contact us at bd@tarveda.com